A Phase II, Open-Label, Randomized, Multicenter Study to Assess the Safety and Cardiovascular Effects of MyoCell Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Post Myocardial Infarction(s)

Trial Profile

A Phase II, Open-Label, Randomized, Multicenter Study to Assess the Safety and Cardiovascular Effects of MyoCell Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Post Myocardial Infarction(s)

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2014

At a glance

  • Drugs Muscle-derived autologous stem cell therapy Bioheart (Primary)
  • Indications Heart failure; Myocardial disorders; Postmyocardial infarction
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SEISMIC
  • Sponsors Bioheart
  • Most Recent Events

    • 25 Apr 2014 New source identified and integrated (ISCTN: Current Controlled Trials)
    • 18 Feb 2014 Status changed from unconfirmed to completed as reported by ISRCTN: Current Controlled Trials
    • 03 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top